Clinical Significance of Serum Syndecan-4 in Patients With Drug-induced Interstitial Lung Disease

被引：0

作者：

Sato, Y. ^{[1
]}

Tanino, Y. ^{[1
]}

Nikaido, T. ^{[1
]}

Togawa, R. ^{[1
]}

Kawamata, T. ^{[1
]}

Watanabe, N. ^{[1
]}

Wang, X. ^{[1
]}

Fukuhara, N. ^{[1
]}

Kazama, K. ^{[1
]}

Yamada, R. ^{[1
]}

Sato, R. ^{[1
]}

Tomita, H. ^{[1
]}

Suzuki, Y. ^{[1
]}

Saito, J. ^{[1
]}

Kanazawa, K. ^{[1
]}

Shibata, Y. ^{[1
]}

机构：

[1] Fukushima Med Univ, Dept Pulm Med, Fukushima, Japan

来源：

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2024年 / 209卷

关键词：

D O I：

暂无

中图分类号：

R4 [临床医学];

学科分类号：

1002 ; 100602 ;

摘要：

A3688

引用

页数：1

共 50 条

[31] Drug-induced interstitial lung disease: mechanisms and best diagnostic approaches
Osamu Matsuno
Respiratory Research, 13
[32] Drug-induced interstitial lung disease (DILD) during treatment with ustekinumab
Sorger, Constantin
Simon, Jan Christoph
Treudler, Regina
HAUTARZT, 2020, 71 (04): : 309 - 312
[33] Serum Syndecan-4 is a Novel Biomarker for Patients With Chronic Heart Failure
Takahashi, Rieko
Negishi, Kazuaki
Watanabe, Ata
Arai, Masashi
Naganuma, Fumio
Ohyama, Yoshiaki
Kaneko, Yoshiaki
Kurabayashi, Masahiko
JOURNAL OF CARDIAC FAILURE, 2010, 16 (09) : S175 - S175
[34] Serum syndecan-4 is a novel biomarker for patients with chronic heart failure
Takahashi, Rieko
Negishi, Kazuaki
Watanabe, Atai
Arai, Masashi
Naganuma, Fumio
Ohyama, Yoshiaki
Kurabayashi, Masahiko
JOURNAL OF CARDIOLOGY, 2011, 57 (03) : 325 - 332
[35] Pharmacovigilance: Drug-induced interstitial Lung Diseases
Simon, Annika
PNEUMOLOGIE, 2025, 79 (03): : 197 - 197
[36] DRUG-INDUCED INTERSTITIAL LUNG-DISEASES
GOCKERMAN, JP
CLINICS IN CHEST MEDICINE, 1982, 3 (03) : 521 - 536
[37] The Ratio KL-6 to SLX in Serum for Prediction of the Occurrence of Drug-Induced Interstitial Lung Disease in Lung Cancer Patients with Idiopathic Interstitial Pneumonias Receiving Chemotherapy
Kashiwabara, Kosuke
Semba, Hiroshi
Fujii, Shinji
Tsumura, Shinsuke
Aoki, Ryota
CANCER INVESTIGATION, 2015, 33 (10) : 516 - 521
[38] Drug-Induced Lung Disease
王林
黄亚明
中华内科杂志, 2011, (09)
[39] Case report: continued treatment with alectinib is possible for patients with lung adenocarcinoma with drug-induced interstitial lung disease
Nitawaki, Tatsuya
Sakata, Yoshihiko
Kawamura, Kodai
Ichikado, Kazuya
BMC PULMONARY MEDICINE, 2017, 17
[40] DRUG-INDUCED LUNG DISEASE
不详
LANCET, 1969, 2 (7621): : 628 - +

← 1 2 3 4 5 →